Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma

[1]  D. Morton,et al.  Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? , 2000, Annals of Surgical Oncology.

[2]  D. Morton,et al.  Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model , 1996, Annals of Surgical Oncology.

[3]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[4]  D. Roses,et al.  Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  D. Speiser,et al.  Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  D. Morton,et al.  Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Frazer,et al.  Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. , 2002, Cancer research.

[8]  R. Elashoff,et al.  Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes , 2002, Annals of surgery.

[9]  V. Sondak,et al.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Machiels,et al.  Peptide-based cancer vaccines. , 2000, Seminars in oncology.

[11]  H. Maguire,et al.  Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. , 2001, International journal of cancer.

[12]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[13]  D. Czerwinski,et al.  Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Khoruts,et al.  In vivo activation of antigen-specific CD4 T cells. , 2001, Annual review of immunology.

[15]  J. Fay,et al.  Dendritic cell based tumor vaccines. , 2000, Immunology letters.

[16]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[17]  M. Colombo,et al.  Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. , 1999, Human gene therapy.

[18]  D. Schadendorf,et al.  Cell-based vaccination against melanoma – background, preliminary results, and perspective , 1999, Journal of Molecular Medicine.

[19]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[21]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[22]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[24]  R. Gupta,et al.  Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Schadendorf,et al.  Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study , 1998, Gene Therapy.

[26]  R. Shapiro,et al.  Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. , 1998, Journal of the National Cancer Institute.

[27]  V. Maino,et al.  Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. , 1998, Journal of immunological methods.

[28]  M. Colombo,et al.  Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability , 1997, Cancer Immunology, Immunotherapy.

[29]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Morton,et al.  Vaccine therapy for malignant melanoma , 1996, CA: a cancer journal for clinicians.

[31]  D. Morton,et al.  Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. , 1994, Cancer research.

[32]  G. Carcelain,et al.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.

[33]  S. Ferrone.  Human Tumor‐Associated Antigen Mimicry by Anti‐idiotypic Antibodies Immunogenicity and Clinical Trials in Patients with Solid Tumors a , 1993, Annals of the New York Academy of Sciences.

[34]  D. Pardoll,et al.  Cancer vaccines. , 1993, Trends in pharmacological sciences.

[35]  P. Hersey,et al.  MHC‐restricted responses of CD8+ AND CD4+ T‐cell clones from regional lymph nodes of melanoma patients , 1992, International journal of cancer.

[36]  M. Herlyn,et al.  Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. , 1989, Cancer research.

[37]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[38]  T. Boon,et al.  Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones , 1988, European journal of immunology.

[39]  S. Canevari,et al.  Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease , 1975, International journal of cancer.

[40]  M. Mastrangelo,et al.  Clinical and immunological significance of human melanoma cytotoxic antibody. , 1975, Cancer research.

[41]  T. Phillips,et al.  Tumour-specific Antibodies in Human Malignant Melanoma and their Relationship to the Extent of the Disease , 1969, British medical journal.

[42]  D. Morton,et al.  Demonstration of antibodies against human malignant melanoma by immunofluorescence. , 1968, Surgery.